Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.

Autor: Buchbinder D; Division of Pediatric Hematology, Children's Hospital of Orange County, Orange, California. Electronic address: dbuchbinder@choc.org., Brazauskas R; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Bo-Subait K; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Ballen K; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia., Parsons S; The Center for Health Solutions at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts., John T; Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas., Hahn T; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee., Steinberg A; Division of Hematology and Oncology, Mount Sinai Hospital, New York, New York., D'Souza A; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Kumar AJ; The Center for Health Solutions at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts., Yoshimi A; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany., Wirk B; Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington., Shaw B; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Freytes C; Texas Transplant Institute, San Antonio, Texas., LeMaistre C; Hematology and Bone Marrow Transplant, Sarah Cannon, Nashville, Tennessee., Bredeson C; Ottawa Hospital Blood and Marrow Transplant Program and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Dandoy C; UC Department of Pediatrics and Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Almaguer D; Hematology Service at the University Hospital in Monterrey Mexico, and the Stem cell Transplantation Program, Hospital Universitario Dr José E. González, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico., Marks DI; Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom., Szwajcer D; Department of Hematology/Oncology, CancerCare Manitoba/University of Manitoba, Winnipeg, Manitoba, Canada., Hale G; Department of Hematology/Oncology, Johns Hopkins All Children's Hospital, St Petersburg, Florida., Schouten H; Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands., Hashem H; Division of Pediatric Hematology/Oncology and Bone marrow Transplantation, King Hussein Cancer Center, Amman, Jordan., Schoemans H; Hematology department and Bone marrow transplant unit, University Hospital Leuven and KU Leuven, Leuven, Belgium., Murthy HS; Mayo Clinic Florida, Jacksonville, Florida., Lazarus HM; Department of Medicine, Case Western Reserve University, Cleveland, Ohio., Cerny J; Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts., Tay J; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Yared JA; Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland., Adekola K; Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Schultz KR; Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada., Lehmann L; Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts., Burns L; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota., Aljurf M; Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia., Diaz MA; Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain., Majhail N; Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio., Farhadfar N; Division of Hematology/Oncology, University Florida College of Medicine, Gainesville, Florida., Kamble R; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas., Olsson R; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden., Schears R; Department of Emergency Medicine, University of Central Florida, Orlando, Florida., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Beattie S; Department of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, Alberta, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Chhabra S; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Badawy S; Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Ganguly S; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas., Ciurea S; MD Anderson Cancer Center, Houston, Texas., Marino S; Department of Pathology, University of Chicago Medicine, Chicago, Illinois., Gergis U; Hematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York., Kuwatsuka Y; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan., Inamoto Y; Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan., Khera N; Department of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona., Hashmi S; Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Wood W; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina., Saber W; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Jazyk: angličtina
Zdroj: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2020 Mar; Vol. 26 (3), pp. 553-561. Date of Electronic Publication: 2019 Nov 11.
DOI: 10.1016/j.bbmt.2019.11.003
Abstrakt: Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.
(Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: